Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Successful Entrepreneurs Share Brand-Building Pointers, Recall Faux Pas

This article was originally published in The Rose Sheet

Executive Summary

At Cosmoprof North America, a trio of industry vets shared with aspiring entrepreneurs their experiences, including some of their most regrettable faux pas, in taking a beauty brand from concept to commercialization.

You may also be interested in...



Borba Teams With Brewer To Market Drinkable Skin Care; QVC Owner Invests

Borba is looking forward to expanded distribution of its drinkable skin-care products and topical cosmeceuticals through a distribution agreement with Anheuser-Busch and the investment of Liberty Media Corporation, owner of QVC

Euromonitor: Value Shopping, Gender-Blurring Among Top Consumer Trends For 2106

A new report from market-research firm Euromonitor International suggests that global consumption in the coming year will see a blend of established, new and counter trends, challenging the way consumers live and shop. Within beauty, marketers may seize on the trends of value shopping, gender-blurring and embracing of aging to reach discriminating consumers in 2016.

P&G Eyes Product Sampling, Trials As Fix For Sagging Sales

Procter & Gamble management highlights product sampling and trials as opportunities to drive home product benefits with consumers at a time when the firm is increasing prices to counter the currency impact of the strong dollar. Analysts pressured P&G CFO Jon Moeller for details on the firm's turnaround following a troublesome quarter.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel